We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+3.36%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$4.51B
AUM Growth
+$737M
(+20%)
Cap. Flow
+$736M
Cap. Flow
% of AUM
16.32%
Top 10 Holdings %
Top 10 Hldgs %
19.25%
Holding
501
New
284
Increased
70
Reduced
66
Closed
74
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$99.4M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$80.7M |
| 3 |
Johnson & Johnson
JNJ
|
+$77.7M |
| 4 |
Electronic Arts
EA
|
+$61.9M |
| 5 |
Danaher
DHR
|
+$60.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$99.3M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$97.8M |
| 3 |
Medtronic
MDT
|
+$68.7M |
| 4 |
NXP Semiconductors
NXPI
|
+$61.6M |
| 5 |
Lumentum
LITE
|
+$58.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 47.83% |
| 2 | Technology | 26.25% |
| 3 | Communication Services | 6.68% |
| 4 | Consumer Discretionary | 4.05% |
| 5 | Financials | 2.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Avantor
AVTR
$9.25B
| $27.3M | 0.6% |
941,944
+34,751
| +4% | +$1M |
|
52
T-Mobile US
TMUS
$190B
| $26.1M | 0.58% |
208,077
+83,797
| +67% | +$10.6M |
|
53
Arista Networks
ANET
$233B
| $25.1M | 0.56% |
+1,329,120
| New | +$24.9M |
|
54
MarketWise
MKTW
$53.6M
| $24.7M | 0.55% |
124,662
-75,777
| -38% | -$15.7M |
|
|
OLK
55
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| $24.3M | 0.54% |
+675,124
| New | +$22.7M |
|
56
Viatris
VTRS
$20.5B
| $24.2M | 0.54% |
1,731,445
+1,385,217
| +400% | +$22.6M |
|
57
Marvell Technology
MRVL
$174B
| $24.1M | 0.54% |
492,597
-21,847
| -4% | -$1.07M |
|
58
Playtika
PLTK
$1.54B
| $23.9M | 0.53% |
+877,619
| New | +$25.8M |
|
59
Allogene Therapeutics
ALLO
$635M
| $23.7M | 0.53% |
672,644
+105,105
| +19% | +$3.55M |
|
|
CCC
60
CCC Intelligent Solutions
CCC
$3.71B
| $23.6M | 0.52% |
2,329,624
+218,804
| +10% | +$2.65M |
|
|
VSPRU
61
DELISTED
Vesper Healthcare Acquisition Corp. Unit
VSPRU
| $23.1M | 0.51% |
2,000,000
| – | – |
|
62
Cullinan Oncology
CGEM
$999M
| $22.6M | 0.5% |
+542,912
| New | +$22M |
|
63
Merck
MRK
$316B
| $22M | 0.49% |
+299,052
| New | +$22.1M |
|
64
Synopsys
SNPS
$75.1B
| $22M | 0.49% |
88,608
+9,779
| +12% | +$2.48M |
|
65
Eli Lilly
LLY
$1,000B
| $21.6M | 0.48% |
115,646
-294,204
| -72% | -$57.5M |
|
66
Ionis Pharmaceuticals
IONS
$9.06B
| $21.4M | 0.47% |
475,891
+144,514
| +44% | +$8.06M |
|
|
67
Amgen
AMGN
$204B
| $21M | 0.47% |
84,361
-416,159
| -83% | -$99.3M |
|
|
ZGNX
68
DELISTED
Zogenix, Inc.
ZGNX
| $20.4M | 0.45% |
1,047,616
-396,970
| -27% | -$8.14M |
|
69
Pfizer
PFE
$143B
| $20.2M | 0.45% |
+557,075
| New | +$19.8M |
|
|
RTPYU
70
DELISTED
Reinvent Technology Partners Y Unit
RTPYU
| $20.1M | 0.45% |
+2,000,000
| New | +$20.1M |
|
71
HCA Healthcare
HCA
$88B
| $19.1M | 0.42% |
101,183
-79,968
| -44% | -$14.1M |
|
72
Maravai LifeSciences
MRVI
$947M
| $18.3M | 0.41% |
513,957
-105,260
| -17% | -$3.49M |
|
73
Broadcom
AVGO
$1.87T
| $18.2M | 0.4% |
+392,400
| New | +$18.1M |
|
74
Nerdy
NRDY
$108M
| $17.8M | 0.4% |
1,799,159
+122,861
| +7% | +$1.34M |
|
|
SAGE
75
DELISTED
Sage Therapeutics
SAGE
| $17.5M | 0.39% |
234,434
+49,876
| +27% | +$4.09M |
|
Similar funds
PAM
TCIIS
UIM
Woodline Partners's Q1 2021 Portfolio in Review
As of Q1 2021, Woodline Partners held 501 positions worth $4.51B, up 20% from $3.77B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Woodline Partners deployed $736M of net new capital in Q1 2021, opening 284 new positions and adding to 70 existing holdings. Its largest new stake was Gilead Sciences: 1,541,893 shares worth $99.7M.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 43% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Amgen, an estimated $99.3M trimmed.
- Woodline Partners's largest Q1 2021 buy was Gilead Sciences: 1,541,893 shares worth $99.7M.
- Woodline Partners added most to Regeneron Pharmaceuticals in Q1 2021, an estimated $80.7M increase.
- Woodline Partners's biggest Q1 2021 reduction was Amgen, cutting an estimated $99.3M.
- Woodline Partners fully exited Alphabet (Google) Class A in Q1 2021, selling an estimated $97.8M.
- Woodline Partners's ten largest holdings make up 19% of its $4.51B portfolio in Q1 2021.
- Woodline Partners opened 284 new positions and closed 74 in Q1 2021.
- Woodline Partners's portfolio value rose 20% quarter-over-quarter to $4.51B.
Based on Woodline Partners's 13F filing for Q1 2021, filed 17 May 2021.